ZSAN - Zosano Pharma Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.1200
-0.1200 (-3.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.2400
Open3.2600
Bid2.2000 x 2900
Ask4.0500 x 1400
Day's Range3.0800 - 3.2800
52 Week Range1.8500 - 6.6500
Volume200,588
Avg. Volume334,822
Market Cap55.296M
Beta (3Y Monthly)4.12
PE Ratio (TTM)N/A
EPS (TTM)-3.0600
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • Benzinga9 days ago

    Zosano Pharma Presents Positive Migraine-ACT Results

    Zosano Pharma Corp  (NASDAQ: ZSAN ) shared positive results of Migraine-ACT scores for Qtrypta therapy. The results were presented at the AHS 61st Annual Scientific Meeting. The study assessed the effectiveness ...

  • GlobeNewswire9 days ago

    Zosano Pharma Presents Migraine-ACT Scores for Qtrypta™ at the American Headache Society (AHS) Annual Scientific Meeting

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of Migraine-ACT scores for Qtrypta™ therapy used over 6-12 months. The Migraine Assessment of Current Therapy (or Migraine-ACT) questionnaire is a standardized evaluation completed by patients to assess the effectiveness of a patient’s acute treatment of migraine therapy, with the highest achievable score being a four. At their 48-week visit, 89% of participants scored greater than three on the Migraine-ACT questionnaire, while more than 75% scored a four out of four, suggesting optimal acute treatment and no need to change that treatment.

  • In Search of That 'Tenbagger'
    TheStreet.com16 days ago

    In Search of That 'Tenbagger'

    Here are 2 stocks worthy of small positions within a well-diversified biotech portfolio for aggressive investors.

  • GlobeNewswire21 days ago

    Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote speech entitled, “A Novel Intracutaneous Microneedle Delivery System for the Acute Treatment of Migraine” at the Pharmaceutics & Advanced Drug Delivery Systems Conference in Paris on July 5, 2019 at 09:15 am CET. Ms. Lewis’ presentation will review Zosano’s novel and proprietary technology platform, the chemistry, manufacturing, and controls of the company’s lead asset, Qtrypta.

  • GlobeNewswire23 days ago

    Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting

    FREMONT, Calif., July 01, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing.

  • GlobeNewswirelast month

    Zosano Pharma Completes Site Qualification Batches at Contract Manufacturing Organization as it Prepares for NDA Submission of Qtrypta™

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has completed manufacturing of site qualification batches at its commercial manufacturing site for Qtrypta, the company’s investigational treatment for migraines in late stage development.  These batches are intended to demonstrate the robustness and reproducibility of the manufacturing process which will be included as part of its planned submission of a New Drug Application (NDA) for Qtrypta in the fourth quarter 2019. "The completion of these site qualification batches forms the basis of our commercial manufacturing process in our NDA and illustrates the scalability of the process as we head toward commercialization activities for Qtrypta at Thermo Fischer, in North Carolina,” said Hayley Lewis, senior vice president, operations at Zosano.

  • GlobeNewswire2 months ago

    Zosano Pharma Reports First Quarter 2019 Financial Results

    Multiple catalysts, including QtryptaTM NDA submission, anticipated in 2019Company bolstered balance sheet to advance proprietary programs and expand applicability of ADAM.

  • ACCESSWIRE2 months ago

    Zosano Pharma Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Zosano Pharma Corp. (NASDAQ: ZSAN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern ...

  • GlobeNewswire2 months ago

    Zosano Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter’s option to purchase additional shares in connection with Zosano’s previously announced public offering of common stock. A total of 5,750,000 shares of common stock have now been sold by Zosano in the offering, resulting in net proceeds to Zosano of approximately $18.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Zosano. As previously announced, Zosano intends to use the net proceeds from the offering to fund its ongoing development and preparation for potential commercialization of Qtrypta™ (M207), and for working capital and general corporate purposes.

  • GlobeNewswire3 months ago

    Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss results for the first quarter of 2019 and provide an operational update. The Company will announce its financial results for this period in a press release to be issued prior to the call. To access the live webcast, please visit the Investor Relations page of the Zosano Pharma website at http://ir.zosanopharma.com/events.cfm.

  • Zosano Pharma Corporation (NASDAQ:ZSAN): Immense Growth Potential?
    Simply Wall St.3 months ago

    Zosano Pharma Corporation (NASDAQ:ZSAN): Immense Growth Potential?

    In December 2018, Zosano Pharma Corporation (NASDAQ:ZSAN) announced its latest earnings update, which showed that losses became smaller relative to the prior year's level as a result of recent tailwi...

  • GlobeNewswire3 months ago

    Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain

    In this analysis, researchers reviewed eight published trials designed in accordance with the Guidance for Industry, “Migraine: Developing Drugs for Acute Treatment”, finalized in February 2018, that recommended using co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) at 2-hours post-treatment. Using the placebo response rates from these various trials, the authors were able to calculate required sample sizes for future trials and compare these calculations to the sample sizes actually used in completed trials.

  • GlobeNewswire3 months ago

    Zosano Announces Pricing of Public Offering of Common Stock

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of its common stock for gross proceeds of $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Zosano.  The offering is expected to close on or about April 11, 2019, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. is the sole book-running manager for the offering. A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on March 27, 2019.

  • GlobeNewswire4 months ago

    Zosano Pharma Announces Proposed Public Offering of Common Stock

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Zosano. In addition, Zosano intends to grant to the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms and conditions.

  • Business Wire4 months ago

    Zosano Pharma Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    Zosano Pharma Corporation , a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2018, as well as recent business highlights.

  • GlobeNewswire4 months ago

    Zosano Pharma Announces Presentation and Participation at the 31st Annual Roth Conference

    FREMONT, Calif., March 11, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief.

  • GlobeNewswire5 months ago

    Zosano Pharma to Host Conference Call on Fourth Quarter and Full Year 2018 Financial Results and Provide Operational and Strategic Update

    FREMONT, Calif., March 07, 2019 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and.

  • GlobeNewswire5 months ago

    Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE5 months ago

    Four Healthcare Stocks Looking to Close Out a Strong Week

    Nearly every day, headlines are popping up surrounding these innovative companies in the healthcare industry as they tackle the prevalent need for qualitative care. Whereas other industries may have different core values and purposes, healthcare companies are tasked with keeping consumers healthy and amid that responsibility, if done correctly, lies the potential for lucrative opportunities. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Zosano Pharma Corporation (ZSAN), Achieve Life Sciences Inc (ACHV), and Aurora Cannabis Inc (ACB) represent four healthcare companies focused on the advancement of the global healthcare industry.

  • ACCESSWIRE5 months ago

    FDA Events Can Send Stocks Soaring: Here's One That Absolutely No One Is Talking About

    Biotech and healthcare stocks are loved by traders for their big price moves, which usually happen when a company makes progress (or faces problems) with their developmental products like drugs and devices. Results from Phase I, II and III clinical studies, and FDA or European approvals (and rejections), can send stocks soaring. Recent examples include Amarin Corp's (AMRN) 3X move in one day, or Zosano Pharma Corporations' (ZSAN) 100% rip on recent study results.

  • ACCESSWIRE5 months ago

    Watch These Tech Stocks Push The Limit

    ParcelPal Technology Inc (PTNYF) (PKG), Sequans Communications S.A. (SQNS), Zosano Pharma Corporation (ZSAN), and EnSync Inc (ESNC) represent 4 tech stocks on the rise on Thursday. The Company's on-demand delivery platform has garnered notoriety for its ease of use. ParcelPal Technology Inc (PTNYF) (PKG) announced towards the end of last month that the Company had formed a partnership with MADD Canada to aid in the continuous fight to prevent impaired driving.

  • What Kind Of Shareholder Owns Most Zosano Pharma Corporation (NASDAQ:ZSAN) Stock?
    Simply Wall St.5 months ago

    What Kind Of Shareholder Owns Most Zosano Pharma Corporation (NASDAQ:ZSAN) Stock?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Zosano Pharma Corporation (NASDAQ:ZSAN) haveRead More...

  • GlobeNewswire5 months ago

    Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta™ for the Acute Treatment of Migraine Disease

    Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced the completion of the second and final goal of the long-term safety study for Qtrypta, in which patients treated migraine attacks over a one year period.  The long-term data generated in this trial reinforced the well-tolerated safety profile and strong efficacy results previously reported in the six-month dosing portion of this safety study and in the randomized Phase 2/3 ZOTRIP pivotal study. Throughout the clinical program, over 5,800 migraine attacks have been treated with Qtrypta to date.

  • GlobeNewswire6 months ago

    Zosano Announces Publication of Positive Data on Qtrypta’s™ Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines

    In this post-hoc analysis, researchers examined the efficacy of Qtrypta™ in treating subsets of patients whose migraines have traditionally been difficult-to-treat and have been associated with poorer outcomes when treated with oral medications. Migraine characteristics including severe pain, duration of migraine of more than 2 hours, awakening with migraine, and the presence of nausea are established factors that predict a poorer response to traditional migraine treatment.